Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.

Joshua F. Heiber, Xiang Xi Xu, Glen N. Barber

Research output: Contribution to journalReview article

6 Scopus citations

Abstract

In the last decade, we have gained significant understanding of the mechanism by which vesicular stomatitis virus (VSV) specifically kills cancer cells. Dysregulation of translation and defective innate immunity are both thought to contribute to VSV oncolysis. Safety and efficacy are important objectives to consider in evaluating VSV as a therapy for malignant disease. Ongoing efforts may enable VSV virotherapy to be considered in the near future to treat drug-resistant ovarian cancer when other options have been exhausted. In this article, we review the development of VSV as a potential therapeutic approach for recurrent or drug-resistant ovarian cancer.

Original languageEnglish (US)
Pages (from-to)805-814
Number of pages10
JournalChinese journal of cancer
Volume30
Issue number12
DOIs
StatePublished - Dec 2011

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.'. Together they form a unique fingerprint.

  • Cite this